MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) Drug Patent Profile
✉ Email this page to a colleague
When do Midazolam Hydrochloride (autoinjector) patents expire, and when can generic versions of Midazolam Hydrochloride (autoinjector) launch?
Midazolam Hydrochloride (autoinjector) is a drug marketed by Rafa Labs Ltd and is included in one NDA.
The generic ingredient in MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) is midazolam hydrochloride. There are nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the midazolam hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Midazolam Hydrochloride (autoinjector)
A generic version of MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) was approved as midazolam hydrochloride by FRESENIUS KABI USA on June 20th, 2000.
Summary for MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 36 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,090 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) at DailyMed |
-patent-expirations.png "MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) drug patent expirations")
Recent Clinical Trials for MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| U.S. Army Office of the Surgeon General | Phase 1 |
See all MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) clinical trials
Anatomical Therapeutic Chemical (ATC) Classes for MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)
US Patents and Regulatory Information for MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rafa Labs Ltd | MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) | midazolam hydrochloride | SOLUTION;INTRAMUSCULAR | 216359-001 | Aug 8, 2022 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
